Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases.

CTP-692

A promising first-in-class approach to broaden the scope of treating schizophrenia

CTP-543

A drug candidate for alopecia areata, a disease with no currently-approved treatments

LATEST NEWS

Jan 22, 2020
Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata

Dec 19, 2019
Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

© 2020 Concert Pharmaceuticals. All rights reserved.
HOME | SITEMAP | CONTACT | TERMS OF USE | PRIVACY POLICY
Back to Top